Comparison of 75 mg and 150 mg Aspirin for prevention of high blood pressure in women who are at higher risk during pregnancy.
Not Applicable
- Conditions
- Health Condition 1: O141- Severe pre-eclampsia
- Registration Number
- CTRI/2023/12/060983
- Lead Sponsor
- Indian Council of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Women with singleton pregnancy 12 to 16 weeks of POG who will found high risk to develop preterm preeclampsia on first trimester Quadruple test
Exclusion Criteria
Hypersensitivity to aspirin or other nsaids
Active peptic ulcer disease
Active bleeding in pregnancy
Severe liver disease
Mother on anticoagulant or anti platelet
Underlying bleeding disorder in mother
Fetus diagnosed with malformation or aneuploidy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Number of screen positive high risk women taking 75mg Aspirin developing preterm PE <br/ ><br>2. Number of screen positive high risk women taking 150 mg Aspirin developing preterm PE <br/ ><br>Timepoint: At 20,24,28,30,32,34,36,37,38,39 &40 weeks of pregnancy
- Secondary Outcome Measures
Name Time Method Fetal Abortion Preterm Birth Birth weight Stillbirth NICU admission Apgar score less than 7 <br/ ><br> Early neonatal death Intracranial bleeding <br/ ><br>Maternal <br/ ><br> Intrapartum Bleeding GI bleed Gestational HT Eclampsia HELLP Abruption Acute kidney injury <br/ ><br> Mode of delivery <br/ ><br> Postpartum Post partum haemorrhage HDU ICU stay Hematoma formation Mortality <br/ ><br>Timepoint: Fetai Time of delivery <br/ ><br>Maternal At 20weeks 24 weeks 28 weeks 30 weeks 32 weeks 34 weeks 36 weeks 37 weeks 38 weeks 39 & 40 weeks of pregnancy <br/ ><br>